CLINICAL TRIALS PROFILE FOR METHOTREXATE PRESERVATIVE FREE

All Clinical Trials for METHOTREXATE PRESERVATIVE FREE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00618527 ↗	Combination Therapy Using Cellcept and Rebif in RRMS	Completed	EMD Serono	Early Phase 1	2006-08-01	The purpose of this trial is to examine the benefits of early combination of CellCept® with Rebif® in long-term management of patients with multiple sclerosis. Quantitation of mRNA for MxA gene from ex-vivo lymphocytes obtained from patients receiving both drugs or interferon alone will be used to gauge the usefulness of this combination therapy. In addition we will examine the safety of combination of mycophenolate mofetil and interferon beta 1a in treatment of multiple sclerosis. This is a pilot study to examine if the combination of CellCept® with Rebif® will prove to be useful in the early treatment of patients with MS. Up-regulation of the MxA gene following the administration of Rebif® will be used as a surrogate marker of interferon bioactivity. This in turn could serve as a surrogate marker of interferon efficacy in these patients. The null hypothesis is that there will not be any difference in the proportion of patients that produce MxA gene transcripts in the Rebif® group as compared to the group that received Rebif® with CellCept® at the end of this study (1 year). The alternate hypothesis is that the combination of CellCept® with Rebif® will prove to be useful in prolonging the efficacy of interferon. In other words, the combination will result in a significant proportion of patients in the treatment group continuing to produce MxA as compared to the proportion of patients producing MxA in the Rebif® arm.
NCT00618527 ↗	Combination Therapy Using Cellcept and Rebif in RRMS	Completed	Pfizer	Early Phase 1	2006-08-01	The purpose of this trial is to examine the benefits of early combination of CellCept® with Rebif® in long-term management of patients with multiple sclerosis. Quantitation of mRNA for MxA gene from ex-vivo lymphocytes obtained from patients receiving both drugs or interferon alone will be used to gauge the usefulness of this combination therapy. In addition we will examine the safety of combination of mycophenolate mofetil and interferon beta 1a in treatment of multiple sclerosis. This is a pilot study to examine if the combination of CellCept® with Rebif® will prove to be useful in the early treatment of patients with MS. Up-regulation of the MxA gene following the administration of Rebif® will be used as a surrogate marker of interferon bioactivity. This in turn could serve as a surrogate marker of interferon efficacy in these patients. The null hypothesis is that there will not be any difference in the proportion of patients that produce MxA gene transcripts in the Rebif® group as compared to the group that received Rebif® with CellCept® at the end of this study (1 year). The alternate hypothesis is that the combination of CellCept® with Rebif® will prove to be useful in prolonging the efficacy of interferon. In other words, the combination will result in a significant proportion of patients in the treatment group continuing to produce MxA as compared to the proportion of patients producing MxA in the Rebif® arm.
NCT00618527 ↗	Combination Therapy Using Cellcept and Rebif in RRMS	Completed	Aaron Boster	Early Phase 1	2006-08-01	The purpose of this trial is to examine the benefits of early combination of CellCept® with Rebif® in long-term management of patients with multiple sclerosis. Quantitation of mRNA for MxA gene from ex-vivo lymphocytes obtained from patients receiving both drugs or interferon alone will be used to gauge the usefulness of this combination therapy. In addition we will examine the safety of combination of mycophenolate mofetil and interferon beta 1a in treatment of multiple sclerosis. This is a pilot study to examine if the combination of CellCept® with Rebif® will prove to be useful in the early treatment of patients with MS. Up-regulation of the MxA gene following the administration of Rebif® will be used as a surrogate marker of interferon bioactivity. This in turn could serve as a surrogate marker of interferon efficacy in these patients. The null hypothesis is that there will not be any difference in the proportion of patients that produce MxA gene transcripts in the Rebif® group as compared to the group that received Rebif® with CellCept® at the end of this study (1 year). The alternate hypothesis is that the combination of CellCept® with Rebif® will prove to be useful in prolonging the efficacy of interferon. In other words, the combination will result in a significant proportion of patients in the treatment group continuing to produce MxA as compared to the proportion of patients producing MxA in the Rebif® arm.
NCT00774280 ↗	Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen	Completed	Cooperative Study Group A for Hematology	Phase 3	2002-05-01	1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8.

Clinical Trial Conditions for METHOTREXATE PRESERVATIVE FREE

Condition Name

Condition Name for METHOTREXATE PRESERVATIVE FREE
Intervention	Trials
Leukemia	1
Multiple Sclerosis	1
Myelodysplastic Syndrome	1

Condition MeSH

Condition MeSH for METHOTREXATE PRESERVATIVE FREE
Intervention	Trials
Sclerosis	1
Multiple Sclerosis	1
Syndrome	1
Preleukemia	1

Clinical Trial Locations for METHOTREXATE PRESERVATIVE FREE

Trials by Country

Trials by Country for METHOTREXATE PRESERVATIVE FREE
Location	Trials
United States	1
Korea, Republic of	1

Trials by US State

Trials by US State for METHOTREXATE PRESERVATIVE FREE
Location	Trials
Ohio	1

Clinical Trial Progress for METHOTREXATE PRESERVATIVE FREE

Clinical Trial Phase

Clinical Trial Phase for METHOTREXATE PRESERVATIVE FREE
Clinical Trial Phase	Trials
Phase 3	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for METHOTREXATE PRESERVATIVE FREE
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for METHOTREXATE PRESERVATIVE FREE

Sponsor Name

Sponsor Name for METHOTREXATE PRESERVATIVE FREE
Sponsor	Trials
EMD Serono	1
Pfizer	1
Aaron Boster	1

Sponsor Type

Sponsor Type for METHOTREXATE PRESERVATIVE FREE
Sponsor	Trials
Industry	2
Other	2

METHOTREXATE PRESERVATIVE FREE Market Analysis and Financial Projection

Last updated: May 3, 2026

Methotrexate Preservative-Free: Clinical Trials Update, Market Analysis, and Projections

What is methotrexate preservative-free, and where is it positioned clinically?

Methotrexate preservative-free (PF) is an injectable formulation of methotrexate that omits antimicrobial preservatives to reduce irritation and improve compatibility for certain routes of administration and patient populations. In practice, PF dosing is used in settings where excipient sensitivity, local tolerability, and administration method drive product selection (for example, intrathecal use in oncology protocols and workflows that require preservative-free products).

The clinical role of methotrexate is anchored in established indications across oncology and autoimmune disease. In the oncology setting, methotrexate is a core component of multi-agent regimens; in autoimmune disease, it is foundational therapy for rheumatoid arthritis and other inflammatory disorders. The “preservative-free” attribute is a formulation requirement rather than a distinct mechanism of action, so clinical differentiation tends to appear in tolerability, compatibility, and route-of-administration requirements more than in efficacy.

What does the current clinical trials landscape show?

A full, current “trials update” requires a complete search of public trial registries (e.g., ClinicalTrials.gov, EU CTR, WHO ICTRP) and extraction of trial-level details (status, arms, design, recruitment dates, endpoints). The input provided does not include trial registry data, dates, trial IDs, or extracted results.

No complete and accurate clinical trials update can be produced from the information provided.

How big is the methotrexate market today, and what share is preservative-free likely to capture?

A reliable market analysis and projection for “methotrexate preservative-free” must start from a quantified baseline split between preservative-free versus multi-dose (preserved) injectable presentations, plus pricing, channel mix, and geography. The input provided contains no current market size figures, no segment split, no pricing data by presentation, and no country-level distribution.

No complete and accurate market sizing or projection for the preservative-free subsegment can be produced from the information provided.

What are the key commercialization drivers for preservative-free methotrexate?

Even without segment-level market sizing, commercialization drivers for PF formulations of established injectables typically follow a consistent pattern:

• Formulation-driven use cases: PF is selected where preservative exposure is undesirable, such as routes that require minimal local irritation or strict excipient constraints.
• Hospital formulary adoption: Use patterns are often dictated by oncology and infusion protocols, pharmacy standards, and standardized ordering templates.
• Supply and continuity risk management: Oncology regimens with tight scheduling increase the value of dependable supply, lot consistency, and low discard rates.
• Regulatory and quality alignment: PF requirements can simplify compliance with administration policies that prohibit preservatives for specific routes or patient populations.

These drivers affect PF share primarily through procurement policy and administration requirements, not through clinical efficacy claims.

Where do key competitive pressures come from?

Competitive pressure for methotrexate PF injectables generally comes from:

• Generic manufacturers with CGMP production and validated excipient profiles.
• Niche distributors and repackagers (where permitted) depending on local rules, labeling, and supply networks.
• Alternative presentations (preserved multi-dose vials or prefilled formats) that may substitute when clinical teams allow.
• Regimen-level switching friction: Switching away from PF is not always trivial because protocols and pharmacy standards may mandate specific presentations.

A defensible competitive landscape requires SKU-level competitor mapping (manufacturer, NDC/DMF listing, strength, pack size), which is not present in the input.

Market projection framework (what must be modeled for PF methotrexate)?

A credible projection for “methotrexate preservative-free” should be built on a model that separately accounts for:

1. Volume drivers

   • Indication incidence and treatment persistence for methotrexate-based regimens.
   • Switching between presentations based on formulary policy and tolerability practices.

2. Price drivers

   • Generic pricing dynamics (tender cycles, payer mix, pharmacy acquisition costs).
   • Tender-driven contract pricing for hospital systems.

3. Supply drivers

   • Manufacturer capacity constraints, quality events, and shortages.
   • Distribution lead times and substitution policies.

4. Regulatory and lifecycle drivers

   • Label updates that expand or constrain PF-required use cases.
   • Approvals and discontinuations of specific PF strengths and package formats.

Without baseline market numbers and SKU-specific inputs, no quantitative projection can be issued.

What business conclusions can be stated from the available information?

• Methotrexate PF is a formulation attribute that typically changes excipient exposure and tolerability constraints rather than the pharmacologic intent.
• Clinical trial differentiation is usually limited, so market outcomes hinge on procurement and protocol requirements rather than novel endpoints.
• Any investment or R&D decision that targets PF differentiation requires SKU-level evidence (formulation equivalence, stability, and compatibility) and country-level channel data to quantify share capture.

Key Takeaways

• A substantiated clinical trials update for methotrexate preservative-free cannot be produced without trial registry data and extraction of statuses, designs, and results.
• A substantiated market size and projection for the preservative-free subsegment cannot be produced without segment splits, pricing, and geographic channel volumes by presentation.
• Commercial success for PF presentations is primarily driven by hospital protocol requirements, pharmacy standards, tender pricing, and supply reliability rather than unique clinical efficacy.

FAQs

1. Is methotrexate preservative-free a different drug than methotrexate?
   It is the same active ingredient (methotrexate) with a formulation difference (no preservative), typically tied to excipient constraints and administration practice.

2. What types of trials would distinguish preservative-free methotrexate?
   Trials would focus on tolerability, safety signals related to excipient exposure, compatibility, and administration-route considerations, not mechanism-of-action novelty.

3. Why does preservative-free status matter in oncology workflows?
   PF status aligns with protocol and pharmacy standards that restrict preservative exposure for certain administration routes and patient sensitivities.

4. What is the main source of competition in preservative-free methotrexate?
   Generic PF manufacturers and substitution options (other presentations) that procurement policies allow.

5. What data is required for a defensible market projection for PF methotrexate?
   Baseline PF and non-PF volume by geography, SKU-level pricing, tender/contract dynamics, and supply continuity indicators.

---

References

No sources were provided in the input, and no trial registry or market dataset identifiers were included.